Please assess the completion status of the following clinical trial:

Trial Title: Effects of Liposomal Bupivacaine for Acute Pain in Hip and Femur Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. age ≥18 years ≤ 70 years~2. Patient's s/p trauma, with confirmed femur and/or hip fractures with a planned admission to the hospital~3. Patient is ambulatory without assistance (e.g. walker, cane, caretaker) prior to incident.~Exclusion Criteria:~1. \>10 hours since presentation to the emergency department~2. History of seizure disorder, recent seizure or a document intra-cranial hemorrhage.~3. Central or peripheral neurologic deficit on presentation~4. Concern or compartment syndrome~5. Associated additional long bone fractures~6. End stage liver failure~7. Renal failure requiring dialysis~8. Pregnancy or breast feeding~9. Prisoners~10. Coagulopathy with INR \>1.5~11. Use of direct thrombin inhibitors (bivalirudin, argatroban, desirudin, dabigatran etexilate), or direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban)~12. Suspected prolonged intubation within first 12 hours secondary to respiratory failure other than peri-procedurally~13. Adults unable to consent~14. Pediatric patients \<18 years old~15. Patients exhibiting signs of shock upon admission, HR \>120 or SBP \<100 mmHg.~16. History of allergic reaction to local anesthetics~17. Administration of any other local anesthetic in the 2 hours prior to the study enrollment.~18. Distal femur fractures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Liposomal Bupivacaine (Type: ACTIVE_COMPARATOR): In patients with femur or hip fractures, a fascia iliaca compartment block using liposomal bupivacaine will be administered
- Ropivacaine HCL (Type: PLACEBO_COMPARATOR): In patients with femur or hip fractures, a fascia iliaca block using using 0.2% ropivacaine will be administered

Based on this trial design, predict the completion outcome and termination type (if applicable).